2022
Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
BEREC, Luděk, Martin ŠMÍD, Lenka PŘIBYLOVÁ, Ondřej MÁJEK, Tomáš PAVLÍK et. al.Základní údaje
Originální název
Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
Autoři
BEREC, Luděk (garant), Martin ŠMÍD, Lenka PŘIBYLOVÁ (203 Česká republika, domácí), Ondřej MÁJEK (203 Česká republika, domácí), Tomáš PAVLÍK (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Milan ZAJÍČEK, Jakub WEINER, Tamara BARUSOVÁ a Jan TRNKA
Vydání
PLoS ONE, Public Library of Science, 2022, 1932-6203
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30303 Infectious Diseases
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.700
Kód RIV
RIV/00216224:14110/22:00126311
Organizační jednotka
Lékařská fakulta
UT WoS
000844536800079
Klíčová slova anglicky
COVID 19; SARS CoV 2; Viral vaccines; Vaccines; Czech Republic; Immunity; Vaccination and immunization; Booster doses
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 4. 1. 2023 11:16, Mgr. Marie Šípková, DiS.
Anotace
V originále
Studies demonstrating the waning of post-vaccination and post-infection immunity against covid-19 generally analyzed a limited range of vaccines or subsets of populations. Using Czech national health data from the beginning of the covid-19 pandemic till November 20, 2021 we estimated the risks of reinfection, breakthrough infection, hospitalization and death by a Cox regression adjusted for sex, age, vaccine type and vaccination status. Vaccine effectiveness against infection declined from 87% at 0-2 months after the second dose to 53% at 7-8 months for BNT162b2 vaccine, from 90% at 0-2 months to 65% at 7-8 months for mRNA-1273, and from 83% at 0-2 months to 55% at 5-6 months for the ChAdOx1-S. Effectiveness against hospitalization and deaths declined by about 15% and 10%, respectively, during the first 6-8 months. Boosters (third dose) returned the protection to the levels observed shortly after dose 2. In unvaccinated, previously infected individuals the protection against infection declined from 97% after 2 months to 72% at 18 months. Our results confirm the waning of vaccination-induced immunity against infection and a smaller decline in the protection against hospitalization and death. Boosting restores the original vaccine effectiveness. Post-infection immunity also decreases over time.